Non-Cystic Fibrosis Bronchiectasis Treatment Market Size in the 7MM is anticipated to increase by 2034, estimates DelveInsight

DelveInsight's "Non-Cystic Fibrosis Bronchiectasis Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of NCFB, historical and forecasted epidemiology, as well as the NCFB market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover Key Insights into the Non-Cystic Fibrosis Bronchiectasis Market with DelveInsight's In-Depth Report @ Non-Cystic Fibrosis Bronchiectasis Market Size [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Non-Cystic Fibrosis Bronchiectasis Market Report

* In January 2025:- Verona Pharma PLC- The primary objective of this study is to assess the effect of ensifentrine vs placebo in addition to standard of care on pulmonary exacerbations, symptoms and quality of life in participants with NCFBE. The study is designed as a pulmonary exacerbation event-driven study where participants will be treated for greater than or equal to 24 weeks and until 120 subjects have experienced at least 1 protocol-defined pulmonary exacerbation.
* In January 2025:- Sanofi- ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of this study is to evaluate efficacy, safety and tolerability with 2 dosing regimens of itepekimab compared with placebo in male and/or female participants with NCFB aged 18 years of age up to 85 years of age (inclusive).
* According to DelveInsight's epidemiology model, in the 7MM, the total diagnosed prevalent cases of NCFB were approximately 1,028,651 in 2023. This number is anticipated to rise during the forecast period (2024-2034), driven by increased awareness and screening, along with advancements in diagnostic techniques.
* In 2023, the US accounted for the highest number of diagnosed prevalent cases of NCFB, with approximately 380,711 cases, while France accounted for the least, with only 37,576 cases.
* Among EU4 and the UK, the UK accounted for the highest number of diagnosed prevalent cases of NCFB, with approximately 224,976 cases in 2023, followed by Spain with approximately 149,236 cases, and Italy with nearly 89,584 cases.
* Among the severity-specific diagnosed prevalent cases of NCFB in EU4 and the UK in 2023, there were approximately 235,481 moderate cases, around 163,649 severe cases, and 152,230 mild cases.
* Among the gender-specific cases of NCFB in the UK in 2023, there were approximately 130,486 cases for females and around 94,490 cases for males.
* In Japan in 2023, the majority of etiology-specific diagnosed prevalent cases of NCFB were attributed to unknown or idiopathic causes, accounting for 32,837 cases.
* In 2023, Japan had approximately 96,580 diagnosed prevalent cases of NCFB..
* The leading Non-Cystic Fibrosis Bronchiectasis Companies such as Insmed, AstraZeneca, Zambon, Renovion, Haisco Pharmaceutical Group, Chiesi Farmaceutici S.p.A, Armata Pharmaceuticals, Verona Pharma, Sanofi, Regeneron Pharmaceuticals, Boehringer Ingelheim, and CSL and others
* Promising Non-Cystic Fibrosis Bronchiectasis Therapies such as Brensocatib, Colistimethatesodium, Trikafta, CHF 6333, S-1226, CMS, BI 1323495, ARINA-1, TIP, ALX-009 , and others

Stay ahead in the Non-Cystic Fibrosis Bronchiectasis Therapeutics Market with DelveInsight's Strategic Report @ Non-Cystic Fibrosis Bronchiectasis Market Outlook [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Non-Cystic Fibrosis Bronchiectasis Epidemiology Segmentation in the 7MM

* Total Non-Cystic Fibrosis Bronchiectasis diagnosed prevalent cases
* Non-Cystic Fibrosis Bronchiectasis severity-specific diagnosed prevalent cases
* Non-Cystic Fibrosis Bronchiectasis gender-specific diagnosed prevalent cases
* Non-Cystic Fibrosis Bronchiectasis etiology-specific diagnosed prevalent cases
* Non-Cystic Fibrosis Bronchiectasis microbiology patients

Download the report to understand which factors are driving Non-Cystic Fibrosis Bronchiectasis epidemiology trends @ Non-Cystic Fibrosis Bronchiectasis Prevalence [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Non-Cystic Fibrosis Bronchiectasis Emerging Drugs

* Brensocatib: Insmed/AstraZeneca

Brensocatib, an oral small-molecule inhibitor targeting dipeptidyl peptidase 1 (DPP1), is being developed by Insmed for the treatment of bronchiectasis, CRSsNP, and other neutrophil-driven conditions. By inhibiting DPP1, brensocatib aims to reduce inflammation by blocking the activation of neutrophil serine proteases (NSPs), such as neutrophil elastase, during neutrophil formation in the bone marrow. Insmed reported positive topline results from the Phase III ASPEN study of brensocatib in patients with NCFB, leading to plans for a New Drug Application (NDA) submission to the US FDA in late 2024. If approved, brensocatib is expected to launch in the US by mid-2025, followed by launches in Europe and Japan in the first half of 2026. In October 2024, Insmed shared positive late-breaking subgroup data from the Phase III ASPEN study of brensocatib for patients with NCFB at the CHEST 2024 Annual Meeting.

* Inhaled Colistimethate Sodium (CMS I-neb): Zambon

CMS I-neb is an investigational inhaled therapy for adults with NCFB colonized by P. aeruginosa, potentially offering a first-in-class treatment option. It uses colistimethate sodium, a prodrug of colistin, a polymyxin antibiotic targeting aerobic Gram-negative pathogens, including drug-resistant P. aeruginosa. By disrupting the bacterial cell membrane, colistin causes cell death and serves as a last-resort treatment for infections like carbapenem-resistant P. aeruginosa. In September 2024, Zambon released the results of the Phase III PROMIS-I and PROMIS-II studies in The Lancet Respiratory Medicine journal.

* FASENRA (benralizumab): AstraZeneca

FASENRA (benralizumab) is a monoclonal antibody that targets the IL-5 receptor alpha on eosinophils, facilitating the recruitment of natural killer cells to induce apoptosis, resulting in rapid and near-complete depletion of blood and tissue eosinophils in most patients. FASENRA is currently under investigation for treating adult patients with Non-Cystic Fibrosis Bronchiectasis associated with eosinophilic inflammation (NCFB + EI). According to clinicaltrials.gov, FASENRA completed Phase III clinical trials for this indication in April 2024.

Non-Cystic Fibrosis Bronchiectasis Treatment Market

The Non-Cystic Fibrosis Bronchiectasis treatment involves several drug classes tailored to manage symptoms, reduce exacerbations, and control underlying inflammation. Antibiotics, both oral and inhaled, are essential for managing chronic bacterial colonization, particularly against pathogens like P. aeruginosa. Macrolides, often used for their anti-inflammatory properties, are beneficial in reducing exacerbation frequency. Bronchodilators, including beta-agonists and anticholinergics, help alleviate airway obstruction, while corticosteroids are used to address inflammation, although their role remains limited due to potential side effects.

Get In-Depth Knowledge on Non-Cystic Fibrosis Bronchiectasis Market Trends and Forecasts with DelveInsight @ Non-Cystic Fibrosis Bronchiectasis Treatment Market [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Non-Cystic Fibrosis Bronchiectasis Market Outlook

The Non-Cystic Fibrosis Bronchiectasis market is poised for significant growth due to the evolving landscape of pharmacological and non-pharmacological interventions addressing the complex pathophysiology of the disease. Current therapeutic strategies encompass a range of drug classes, including antibiotics, corticosteroids, bronchodilators, and mucolytics, with inhaled antibiotics demonstrating efficacy in managing chronic bacterial infections and reducing exacerbation rates.

Scope of the Non-Cystic Fibrosis Bronchiectasis Market Report

* Coverage- 7MM
* Study Period- 2020-2034
* Non-Cystic Fibrosis Bronchiectasis Companies- Insmed, AstraZeneca, Zambon, Renovion, Haisco Pharmaceutical Group, Chiesi Farmaceutici S.p.A, Armata Pharmaceuticals, Verona Pharma, Sanofi, Regeneron Pharmaceuticals, Boehringer Ingelheim, and CSL and others
* Non-Cystic Fibrosis Bronchiectasis Therapies- Brensocatib, Colistimethatesodium, Trikafta, CHF 6333, S-1226, CMS, BI 1323495, ARINA-1, TIP, ALX-009 , and others
* Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment: Non-Cystic Fibrosis Bronchiectasis Current marketed and Non-Cystic Fibrosis Bronchiectasis Emerging Therapies
* Non-Cystic Fibrosis Bronchiectasis Market Dynamics: Non-Cystic Fibrosis Bronchiectasis Market drivers and Non-Cystic Fibrosis Bronchiectasis Market Barriers

Unlock Strategic Insights with DelveInsight's Comprehensive Non-Cystic Fibrosis Bronchiectasis Market Report @ Non-Cystic Fibrosis Bronchiectasis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Key Insights

2. Report Introduction

3. Market Overview at a Glance

4. Epidemiology and Market Forecast Methodology

5. Executive Summary

6. Key Events

7. Disease Background and Overview

8. Patient Journey

9. Epidemiology and Patient Population

10. Emerging Drugs

11. Non-Cystic Fibrosis Bronchiectasis (NCFB): Market Analysis

12. Key Opinion Leaders' Views

13. SWOT Analysis

14. Unmet Needs

15. Market Access and Reimbursement

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=noncystic-fibrosis-bronchiectasis-treatment-market-size-in-the-7mm-is-anticipated-to-increase-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/sepsis-market



This release was published on openPR.